Zacks Investment Research
29 Oct 2026, 15:46 UTC · 2h ago
BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises
Impact · against what's priced in
BHC is seeing a significant positive catalyst as Q3 earnings and revenues substantially beat consensus, driven by accelerating organic growth in the Salix segment. The 64% EPS beat and Xifaxan's 16% growth suggest a fundamental upward shift in the company's earnings trajectory.
- BHC+0.70
No priced-in read yet
- In context
Adjusted EPS of $1.77 beat the $1.08 consensus by 64%, and Salix revenues of $831 million exceeded estimates by over $120 million, indicating stronger-than-expected growth drivers.
Read from the article alone
